Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

Similar articles for PubMed (Select 23855527)

1.

Concerns regarding BRAF testing algorithm.

Clark RR, Garioch JJ, Moncrieff MD.

Br J Dermatol. 2013 Nov;169(5):1167-8. doi: 10.1111/bjd.12508. No abstract available.

PMID:
23855527
2.

Concerns regarding BRAF testing algorithm: reply from authors.

Gonzalez D, Fearfield L, Nathan P, Tanière P, Wallace A, Brown E, Harwood C, Marsden J, Whittaker S.

Br J Dermatol. 2013 Nov;169(5):1168-70. doi: 10.1111/bjd.12509. No abstract available.

PMID:
23855556
3.

Community experience of vemurafenib for BRAF(V600) melanoma.

Hersey P.

Lancet Oncol. 2014 Apr;15(4):369-70. doi: 10.1016/S1470-2045(14)70079-8. Epub 2014 Feb 27. No abstract available.

PMID:
24582506
4.

Vemurafenib therapy for stage IV melanoma with V600G-mutation.

Lang N, Weisser A, Enk A, Hassel JC.

J Dtsch Dermatol Ges. 2013 Dec;11(12):1198-9. doi: 10.1111/ddg.12200. Epub 2013 Sep 9. No abstract available.

PMID:
24016000
5.

BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.

Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, Mourah S.

Melanoma Res. 2014 Aug;24(4):415-8. doi: 10.1097/CMR.0000000000000088. No abstract available.

PMID:
24933605
6.

Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.

Starz H, Gutschi M, Welzel J, Haas C.

J Dtsch Dermatol Ges. 2014 Feb;12(2):151-4. doi: 10.1111/ddg.12231. Epub 2013 Nov 18. No abstract available.

PMID:
24238398
7.

[Treatment of metastatic melanoma with BRAF inhibitors].

Hafner C.

Hautarzt. 2011 Sep;62(9):696-8. doi: 10.1007/s00105-011-2232-8. German. No abstract available.

PMID:
21863388
8.

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.

Gonzalez D, Fearfield L, Nathan P, Tanière P, Wallace A, Brown E, Harwood C, Marsden J, Whittaker S.

Br J Dermatol. 2013 Apr;168(4):700-7. doi: 10.1111/bjd.12248. Review.

PMID:
23360189
9.

Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.

Koers K, Francken AB, Haanen JB, Woerdeman LA, van der Hage JA.

J Clin Oncol. 2013 Jun 1;31(16):e251-3. doi: 10.1200/JCO.2012.45.3845. Epub 2013 Apr 8. No abstract available.

10.

Vemurafenib: a guide to its use in unresectable or metastatic melanoma.

Keating GM, Lyseng-Williamson KA.

Am J Clin Dermatol. 2013 Feb;14(1):65-9. doi: 10.1007/s40257-012-0007-3.

PMID:
23329082
11.

New drug for metastatic melanoma increases survival rate.

Carter D.

Am J Nurs. 2011 Sep;111(9):16. doi: 10.1097/01.NAJ.0000405045.85205.90. No abstract available.

PMID:
21865918
12.

Strides in melanoma announced: maximizing value comes next.

Tuma RS.

J Natl Cancer Inst. 2011 Jul 6;103(13):997-9. doi: 10.1093/jnci/djr254. Epub 2011 Jun 21. No abstract available.

13.

[BRAF mutation detection in metastatic melanoma].

Dietel M, Enk A, Lehmann A, Bauer J, Garbe C, Kellner U, Kirchner T, Jung A, Kreipe H, Merkelbach-Bruse S, Büttner R, Rüschoff J, Schlake W, Schirmacher P, Penzel R, Stadler R.

Pathologe. 2012 Jul;33(4):352-6. doi: 10.1007/s00292-012-1609-5. German. No abstract available.

PMID:
22692278
14.

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R.

J Transl Med. 2010 Jul 14;8:67. doi: 10.1186/1479-5876-8-67.

15.

Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?

Saint-Jean M, Quéreux G, Nguyen JM, Peuvrel L, Brocard A, Vallée A, Knol AC, Khammari A, Denis MG, Dréno B.

J Invest Dermatol. 2014 May;134(5):1468-70. doi: 10.1038/jid.2013.378. Epub 2013 Sep 11. No abstract available.

16.

Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.

D'Alonzo D, Glatz K.

Mayo Clin Proc. 2013 Dec;88(12):e151-2. doi: 10.1016/j.mayocp.2013.04.033. No abstract available.

PMID:
24290130
17.

Vemurafenib: the first drug approved for BRAF-mutant cancer.

Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P.

Nat Rev Drug Discov. 2012 Nov;11(11):873-86. doi: 10.1038/nrd3847. Epub 2012 Oct 12. Review.

PMID:
23060265
18.

To B-(RAF) or not to be.

Dummer R, Goldinger SM, Widmer D, Dreier J, Levesque MP.

J Invest Dermatol. 2014 May;134(5):1200-1. doi: 10.1038/jid.2014.62.

19.

Overcoming metastatic melanoma with BRAF inhibitors.

Hong S, Hong S, Han SB.

Arch Pharm Res. 2011 May;34(5):699-701. doi: 10.1007/s12272-011-0521-5. Review.

PMID:
21656352
20.

Vemurafenib in melanoma with BRAF V600E mutation.

Lott JP.

N Engl J Med. 2011 Oct 13;365(15):1449-50; author reply 1450. doi: 10.1056/NEJMc1108651#SA3. No abstract available.

PMID:
21995400
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk